Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2333-2342

  Rich, Fenella J ^a   Kuhn, Sabine ^a   Hyde, Evelyn J ^a   Harper, Jacquie L ^a   Ronchese, Franca ^a   Kirman, Joanna R ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

BCG; Dendritic cell; Immunotherapy; Mycobacteria; Mycobacterium smegmatis; Thymoma

Indexed keywords

CD11B ANTIGEN; CD40 ANTIGEN; GLYCOPROTEIN P 15095;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; LYMPH NODE; MOUSE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THERAPY EFFECT; THYMOMA; TUMOR IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; IMMUNOTHERAPY; INFLAMMATION; LYMPH NODES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM SMEGMATIS; THYMOMA; THYMUS NEOPLASMS;

EID: 84870992363     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1291-8     Document Type: Article

References (43)

1. Coley WB (1910) The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 3 (Surg Sect):1-48
2. Grange JM, Bottasso O, Stanford CA, Stanford JL (2008) The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 26(39):4984-4990. doi:10.1016/j.vaccine.2008. 06.092
3. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R (2011) Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011:405310. doi:10.1155/2011/405310
4. Jo EK (2008) Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs. Curr Opin Infect Dis 21(3):279-286. doi:10.1097/QCO.0b013e3282f88b5d
5. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: Involvement of toll-like receptors. Infect Immun 68(12):6883-6890
6. Gnjatic S, Sawhney NB, Bhardwaj N (2010) Toll-like receptor agonists: Are they good adjuvants? Cancer J 16(4):382-391. doi: 10.1097/PPO.0b013e3181eaca65
7. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180-183
8. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997-1008. doi:10.1016/j.eururo. 2011.03.017
9. Shelley MD, Mason MD, Kynaston H (2010) Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. Cancer Treat Rev 36(3):195-205. doi: 10.1016/j.ctrv.2009.12.005
10. Bevers RF, Kurth KH, Schamhart DH (2004) Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 91(4):607-612. doi:10.1038/sj.bjc.6602026
11. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Tetu B, Lacombe L, Fradet Y (2009) Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur Urol 55(6):1386-1395. doi:10.1016/j.eururo.2009.01.040
12. Higuchi T, Shimizu M, Owaki A, Takahashi M, Shinya E, Nishimura T, Takahashi H (2009) A possible mechanism of intravesical BCG therapy for human bladder carcinoma: Involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother 58(8):1245-1255. doi: 10.1007/s00262-008-0643-x
13. Beatty JD, Islam S, North ME, Knight SC, Ogden CW (2004) Urine dendritic cells: A noninvasive probe for immune activity in bladder cancer? BJU Int 94(9):1377-1383. doi:10.1111/j.1464-410X.2004.05176.x
14. Young SL, Murphy M, Zhu XW, Harnden P, O'Donnell MA, James K, Patel PM, Selby PJ, Jackson AM (2004) Cytokinemodified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int J Cancer 112(4):653-660. doi:10.1002/ijc. 20442
15. Rakshit S, Ponnusamy M, Papanna S, Saha B, Ahmed A, Nandi D (2011) Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: Critical roles of IFNgamma. Int J Cancer. doi:10.1002/ijc.26099
16. Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S (2011) An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann Oncol. doi: 10.1093/annonc/mdr363
17. Stanford JL, Stanford CA, O'Brien ME, Grange JM (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44(2):224-227. doi:10.1016/j.ejca.2007.08.021
18. Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ (2008) An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 44(2):216-223. doi:10.1016/j.ejca.2007.11.003
19. Yarkoni E, Rapp HJ (1980) Immunotherapy of experimental cancer by intralesional injection of emulsified nonliving mycobacteria: Comparison of Mycobacterium bovis (BCG), Mycobacterium phlei, and Mycobacterium smegmatis. Infect Immun 28(3):887-892
20. Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54(6):777-785
21. Rosas M, Thomas B, Stacey M, Gordon S, Taylor PR (2010) The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B. J Leukoc Biol 88(1):169-180. doi:10.1189/jlb.0809548
22. Leon B, Lopez-Bravo M, Ardavin C (2005) Monocyte-derived dendritic cells. Semin Immunol 17(4):313-318. doi:10.1016/ j.smim.2005.05.013
23. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. Science 327(5966):656-661. doi:10.1126/science.1178331
24. Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV (2003) The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European organisation for research and treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44(4):423-428
25. Pierre-Audigier C, Jouanguy E, Lamhamedi S, Altare F, Rauzier J, Vincent V, Canioni D, Emile JF, Fischer A, Blanche S, Gaillard JL, Casanova JL (1997) Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency. Clin Infect Dis 24(5):982-984
26. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168(9):4620-4627
27. Cheadle EJ, O'Donnell D, Selby PJ, Jackson AM (2005) Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 73(2):784-794. doi:10.1128/IAI.73. 2.784-794.2005
28. Leon B, Lopez-Bravo M, Ardavin C (2007) Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26(4):519-531. doi:10.1016/j.immuni.2007. 01.017
29. Nakano H, Lin KL, Yanagita M, Charbonneau C, Cook DN, Kakiuchi T, Gunn MD (2009) Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol 10(4):394-402. doi:10.1038/ ni.1707
30. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, Caux C, Ait-Yahia S, Vicari A, Kaiserlian D, Dubois B (2006) Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8? T cell crosspriming in vivo. Immunity 24(2):191-201. doi:10.1016/j.immuni. 2006. 01.005
31. Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA (2009) Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci USA 106(48):20377-20381. doi:10.1073/pnas.0910295106
32. Palframan RT, Jung S, Cheng G, Weninger W, Luo Y, Dorf M, Littman DR, Rollins BJ, Zweerink H, Rot A, von Andrian UH (2001) Inflammatory chemokine transport and presentation in HEV: A remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med 194(9):1361-1373
33. Reljic R, Di Sano C, Crawford C, Dieli F, Challacombe S, Ivanyi J (2005) Time course of mycobacterial infection of dendritic cells in the lungs of intranasally infected mice. Tuberculosis (Edinb) 85(1-2):81-88. doi:10.1016/j.tube.2004.09.006
34. Schreiber HA, Harding JS, Hunt O, Altamirano CJ, Hulseberg PD, Stewart D, Fabry Z, Sandor M (2011) Inflammatory dendritic cells migrate in and out of transplanted chronic mycobacterial granulomas in mice. J Clin Invest 121(10):3902-3913. doi: 10.1172/JCI45113
35. Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F (2008) Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 57(11):1665-1673. doi:10.1007/s00262-008-0487-4
36. Gerner MY, Casey KA, Mescher MF (2008) Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 181(1):155-164. doi: 181/1/155
37. Gerner MY, Mescher MF (2009) Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 182(5):2726-2737. doi:10.4049/jimmunol.0803479
38. Ataera H, Hyde E, Price KM, Stoitzner P, Ronchese F (2011) Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One 6(3):e17515. doi: 10.1371/journal.pone.0017515
39. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480-489. doi:10.1038/nature 10673
40. Helmich BK, Dutton RW (2001) The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: Factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 166(11):6500-6508
41. Hollenbaugh JA, Dutton RW (2006) IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 177(5):3004-3011. doi:177/5/3004
42. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4? CD25? T cell-mediated suppression by dendritic cells. Science 299(5609):1033-1036. doi:10.1126/science.1078231
43. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, Brown M, Blazar BR, Abramson SB, Lafaille JJ, Dustin ML (2010) Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 328(5976):372-376. doi:10.1126/ science.1186068